Results 31 to 40 of about 418,673 (161)

Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]

, 2010
Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Deepson S Shyangdan, Christine Clar, Pawana Sharma, Royle, Pamela L, Sharma Pawana, Royle Pamela L, Clar, Christine, Clar, C., Waugh, Norman R, Waugh Norman R, Pamela L Royle, Shyangdan Deepson S, Clar Christine, Waugh, Norman, Norman R Waugh, Sharma, Pawana, Shyangdan, D. (Deepson), Shyangdan, Deepson S, Royle, Pamela   +18 more
core   +2 more sources

Efficacy of Glargine Insulin Compared with Neutral Protamine Hagedorn Insulin in Patients with Type 2 Diabetes not Controlled with Oral Hypoglycemics: A Cohort Study

Pakistan Armed Forces Medical Journal, 2023
Objective: To compare the efficacy of Glargine Insulin with Neutral Protamine Hagedorn (NPH) Insulin in patients with uncontrolled type 2 diabetes with oral hypoglycemic. Study Design: Prospective cohort study.
Ebtihal Bilal, Shamaila Burney, Muhammad Usman Sajid, Nabila Shaukat, Muhammad Farooq   +4 more
doaj   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

Impact of switching from neutral protamine hagedorn insulin (NPH) to glargine insulin on glycemic control and clinical outcomes in pediatric patients with type 1 diabetes

Exploratory Research in Clinical and Social Pharmacy
Background: Treatment of type 1 diabetes requires insulin therapy, and various types of insulin can be used. Insulin glargine has been shown to provide effective glycemic control with reduced hypoglycemia.
Hiba Abdelmunim Suliman Elsheikh, Safaa Badi, Ahmed Hafiz Kamal, Mazen Karar, Mohamed Fouad, Omar Khalid, Omnia Abdullah, Setana Mamoun   +7 more
doaj   +1 more source

Analysis of Suffix Use for Biosimilar Product Identification in Postmarketing Adverse Event Reporting

Clinical Pharmacology &Therapeutics, EarlyView.
Accurate identification of medicines used in adverse event reports is crucial for effective postmarketing safety surveillance. The US Food and Drug Administration's (FDA) four‐letter suffix naming convention was designed to facilitate accurate biological product identification, but the extent to which these suffixes have been incorporated into ...
Danijela Stojanovic, Lisa Wolf, M. Stacey Ricci, Monica A. Muñoz   +3 more
wiley   +1 more source

Role of Myotonic Dystrophy Protein Kinase [DMPK] in Glucose Homeostasis and Muscle Insulin Action [PDF]

, 2007
Myotonic dystrophy 1 (DM1) is caused by a CTG expansion in the 3′-unstranslated region of the DMPK gene, which encodes a serine/threonine protein kinase. One of the common clinical features of DM1 patients is insulin resistance, which has been associated
Liesa Marc, Ciaraldi, Theodore P, Martí, Luc, Ciaraldi, Theodore P., Palacin, Manuel, Catalucci, Daniele, Wolfgang H Dillmann, Esther Llagostera, Perla Kaliman, Catalucci Daniele, Camps, Marta, Reddy, Sita, Gomis, Ramon, 1946-, Luc Marti, Llagostera Martín, Esther, Antonio Zorzano, Ciaraldi Theodore P., Dillmann, Wolfgang H, Llagostera Esther, Gomis Ramon, Reddy Sita, Camps Marta, Dillmann, Wolfgang H., Kaliman Perla, Sita Reddy, Kaliman, Perla, Ruiz-Lozano Pilar, Llagostera, Esther, Richard Kondo, Ruiz-Lozano, Pilar, Zorzano Olarte, Antonio, Manuel Palacin, Zorzano Antonio, Kondo, Richard, Palacín Prieto, Manuel, Ramon Gomis, Daniele Catalucci, Liesa Torre-Marín, Montserrat, Dillmann Wolfgang H., Marti Luc, Camps Camprubí, Marta, Zorzano, Antonio, Marta Camps, Pilar Ruiz-Lozano, Liesa, Marc, Kondo Richard, Gomis, Ramon, Marc Liesa, Theodore P Ciaraldi, Palacin Manuel   +49 more
core   +2 more sources

Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice

Journal of Diabetes Research, 2021
Insulin treatment was confirmed to reduce insulin resistance, but the underlying mechanism remains unknown. Caveolin-1 (Cav-1) is a functional protein of the membrane lipid rafts, known as caveolae, and is widely expressed in mammalian adipose tissue ...
Hangya Peng, Panwei Mu, Haicheng Li, Shuo Lin, Chuwen Lin, Keyi Lin, Kunying Liu, Wen Zeng, Longyi Zeng   +8 more
doaj   +1 more source

Considerations for the Integration of Clinical Trials and Real‐World Data

Clinical Pharmacology &Therapeutics, EarlyView.
As clinical decision‐making increasingly moves toward individualized and context‐specific treatment recommendations, reliance on any single evidence source, randomized or observational, may be insufficient. Principled integration of randomized controlled trials and real‐world data, grounded in explicit causal frameworks, offers a path toward evidence ...
Sky Qiu, Charles E. Barr, Lauren Dang, Larry Han, Kajsa Kvist, Hana Lee, Andrew Mertens, Nerissa Nance, Lei Nie, Kara Rudolph, Xu Shi, Jens Tarp, Salina P. Waddy, Kenneth Wiley, Andy Wilson, Margot Lisa Jing Yann, Zhiwei Zhang, Tianyue Zhou, Maya Petersen, Mark van der Laan   +19 more
wiley   +1 more source

When "flawed" translates into "flood": the unproven association between cancer incidence and glargine insulin therapy

, 2009
A few months ago, a hot spot emerged in the area of diabetes and cancer epidemiology. Hemkens et al., from the Institute for Quality and Efficiency in Health Care, published in Diabetologia a report of an observational cohort study based on a large ...
Meigs, James B, Miguel Yanes, José María De   +1 more
core   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source